About FluoGuide

FluoGuide, founded in 2018, takes precision surgery to the next level, improving the outcome for cancer patients. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer intraoperatively. This improved precision enabled by FluoGuide’s products is expected to have a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, this improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs.

The Company has published key results on the efficacy of FG001 as well as showing it was well tolerated and safe from clinical trials in patients with aggressive brain cancer (high-grade glioma) that undergo surgery. In addition, FluoGuide has demonstrated the effect of FG001 in lung and head & neck cancers.

FluoGuide, committed to reducing local cancer recurrence and surgical complications, strives to significantly enhance patient outcomes with its innovative products while also aiming to lower healthcare costs. The company, listed on the Nasdaq First North Growth Market in Sweden, is advancing its product pipeline with the aim of addressing multiple cancer indications.

Learn more about our uPAR-based technology platform and our lead product FG001